Published in Clin Cancer Res on December 10, 2013
Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine. Epidemiology (2016) 1.89
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer (2014) 1.46
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med (2014) 1.07
Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94
Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2015) 0.94
A molecular signature for the prediction of recurrence in colorectal cancer. Mol Cancer (2015) 0.82
Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology (2016) 0.81
Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer. Clin Epigenetics (2015) 0.81
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. Br J Cancer (2014) 0.78
Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry. Genes Chromosomes Cancer (2014) 0.76
MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res (2016) 0.76
Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prev Res (Phila) (2017) 0.75
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Pancreas (2016) 0.75
Co-Inflammatory Roles of TGFβ1 in the Presence of TNFα Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells. Front Immunol (2017) 0.75
Rectal Cancer in a Patient with Bartter Syndrome: A Case Report. Genes (Basel) (2017) 0.75
Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus. Biomedicines (2017) 0.75
Association of colonoscopy and death from colorectal cancer. Ann Intern Med (2008) 15.51
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999) 6.73
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (2012) 4.85
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology (2007) 4.06
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs (2005) 3.10
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology (2003) 2.96
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65
Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst (1993) 2.52
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem (2001) 2.41
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med (2013) 2.33
Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26
Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer (2012) 2.26
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res (2009) 2.25
NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med (2007) 2.19
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 2.06
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med (2006) 1.76
Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer (2012) 1.54
Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci (1998) 1.44
Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc Natl Acad Sci U S A (1979) 1.43
Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess (2010) 1.40
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol (2000) 1.31
Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci U S A (2010) 1.26
Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem (1998) 1.24
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer (2004) 1.24
Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut (2010) 1.20
Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J (2001) 1.17
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer (2010) 1.17
Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis (2006) 1.16
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology (1998) 1.16
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev (2004) 0.97
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene (2010) 0.95
Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut (2011) 0.90
A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev (2002) 0.90
The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials (2011) 0.89
Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis (2010) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther (2011) 4.39
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res (2002) 1.92
BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res (2008) 1.80
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res (2009) 1.45
Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol (2010) 1.40
Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy (2010) 1.37
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res (2008) 1.35
Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res (2002) 1.34
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest (2004) 1.33
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther (2010) 1.31
Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One (2012) 1.30
Sporadic colorectal cancer: an infectious disease? Gastroenterology (2007) 1.26
Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem (2011) 1.19
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer (2004) 1.16
Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol (2011) 1.11
PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem (2006) 1.11
Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res (2006) 1.11
Radiation enteritis. Curr Gastroenterol Rep (2002) 1.10
The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc (2010) 1.08
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol (2005) 1.04
A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res (2010) 1.02
Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther (2012) 1.01
The future role of the gastroenterologist in digestive oncology: an international perspective. Gastroenterology (2011) 1.01
Chemoprevention of colorectal cancer. Am J Gastroenterol (2002) 0.98
N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer (2005) 0.98
Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol (2012) 0.97
Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol (2015) 0.96
Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res (2012) 0.95
p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosome. J Biol Chem (2013) 0.93
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol (2012) 0.93
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One (2013) 0.91
A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev (2002) 0.90
A population-based study of prevalence and adherence trends in average risk colorectal cancer screening, 1997 to 2008. Cancer Epidemiol Biomarkers Prev (2011) 0.86
Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2002) 0.86
Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther (2005) 0.82
HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer (2013) 0.81
Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol (2006) 0.81
Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun (2002) 0.81
Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet? J Natl Cancer Inst (2012) 0.81
Communication of genetic test results to family and health-care providers following disclosure of research results. Genet Med (2013) 0.81
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica (2013) 0.79
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics (2016) 0.79
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett (2006) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
Insights into familial colon cancer: the plot thickens. Clin Gastroenterol Hepatol (2005) 0.78
Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther (2013) 0.78
Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma. Int J Cancer (2002) 0.78
Legionnaires' disease caused by Legionella pneumophila serogroups 5 and 10, China. Emerg Infect Dis (2014) 0.77
Serrated polyps of the colon. F1000 Med Rep (2010) 0.77
Treating polyps in ulcerative colitis: adenoma-like lesions and dysplasia-associated mass lesions. Clin Gastroenterol Hepatol (2004) 0.75
[Etiology monitoring of influenza virus and variation in hemagglutinin genes of H13 subtype in Wuxi area]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2009) 0.75
A moveable feast. Clin Gastroenterol Hepatol (2007) 0.75
Species C is Predominant in Chinese Children with Acute Respiratory Adenovirus Infection. Pediatr Infect Dis J (2015) 0.75